Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial.
Hall N, Allavena C, Katlama C, Jobert A, Molina JM, Cua E, Bani-Sadr F, Hocqueloux L, Duvivier C, Merrien D, Hikombo H, André-Garnier E, Gaultier A, Raffi F; QDISS Study Group. Hall N, et al. Among authors: duvivier c. AIDS Res Ther. 2022 Jan 15;19(1):4. doi: 10.1186/s12981-022-00428-5. AIDS Res Ther. 2022. PMID: 35033092 Free PMC article.
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG. Soulié C, et al. Among authors: duvivier c. AIDS. 2009 Jul 31;23(12):1605-8. doi: 10.1097/QAD.0b013e32832d9031. AIDS. 2009. PMID: 19487903 Clinical Trial.
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, Fourn E, Duvivier C, Simon A, Courbon E, Murphy R, Flandre P, Peytavin G, Katlama C; RADAR Study Group. Ghosn J, et al. Among authors: duvivier c. J Med Virol. 2013 Jan;85(1):8-15. doi: 10.1002/jmv.23404. Epub 2012 Sep 28. J Med Virol. 2013. PMID: 23024008 Clinical Trial.
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat’AIDS Study group. Allavena C, et al. Among authors: duvivier c. Infect Dis (Lond). 2016;48(5):392-8. doi: 10.3109/23744235.2015.1133927. Epub 2016 Jan 13. Infect Dis (Lond). 2016. PMID: 26757613 Clinical Trial.
Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.
Cotte L, Ferry T, Pugliese P, Valantin MA, Allavena C, Cabié A, Poizot-Martin I, Rey D, Duvivier C, Cheret A, Dellamonica P, Pradat P, Parienti JJ; Dat’AIDS study group. Cotte L, et al. Among authors: duvivier c. PLoS One. 2017 Feb 2;12(2):e0170661. doi: 10.1371/journal.pone.0170661. eCollection 2017. PLoS One. 2017. PMID: 28152047 Free PMC article.
388 results